UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Fusion Protein:NF1-ASIC2 |
Fusion Protein Summary |
Fusion gene summary |
Fusion partner gene information | Fusion gene name: NF1-ASIC2 | FusionPDB ID: 58671 | FusionGDB2.0 ID: 58671 | Hgene | Tgene | Gene symbol | NF1 | ASIC2 | Gene ID | 4763 | 40 |
Gene name | neurofibromin 1 | acid sensing ion channel subunit 2 | |
Synonyms | NFNS|VRNF|WSS | ACCN|ACCN1|ASIC2a|BNC1|BNaC1|MDEG|hBNaC1 | |
Cytomap | 17q11.2 | 17q11.2-q12 | |
Type of gene | protein-coding | protein-coding | |
Description | neurofibrominneurofibromatosis 1neurofibromatosis-related protein NF-1truncated neurofibromin 1 | acid-sensing ion channel 2acid sensing (proton gated) ion channel 2amiloride-sensitive cation channel 1, neuronalbrain sodium channel 1mammalian degenerin homologneuronal amiloride-sensitive cation channel 1 | |
Modification date | 20200322 | 20200313 | |
UniProtAcc | P21359 | Q16515 | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000356175, ENST00000358273, ENST00000417592, ENST00000431387, ENST00000444181, ENST00000581113, | ENST00000448983, ENST00000225823, ENST00000359872, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 47 X 26 X 21=25662 | 18 X 14 X 7=1764 |
# samples | 69 | 19 | |
** MAII score | log2(69/25662*10)=-5.21689344093196 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(19/1764*10)=-3.21477923722657 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: NF1 [Title/Abstract] AND ASIC2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | NF1(29560231)-ASIC2(31439085), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | NF1-ASIC2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NF1-ASIC2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | NF1 | GO:0043547 | positive regulation of GTPase activity | 2121371 |
Fusion gene breakpoints across NF1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across ASIC2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
Fusion gene information from FusionGDB2.0. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | SARC | TCGA-DX-A3M1-01A | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - |
ChimerKB3 | . | . | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | |
ChimerKB3 | . | . | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - |
Top |
Fusion ORF Analysis |
Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000356175 | NF1 | chr17 | 29560231 | + | ENST00000225823 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000356175 | NF1 | chr17 | 29560231 | + | ENST00000359872 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000358273 | NF1 | chr17 | 29560231 | + | ENST00000225823 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000358273 | NF1 | chr17 | 29560231 | + | ENST00000359872 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000356175 | NF1 | chr17 | 29560231 | + | ENST00000225823 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000356175 | NF1 | chr17 | 29560231 | + | ENST00000359872 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000358273 | NF1 | chr17 | 29560231 | + | ENST00000225823 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
ENST00000358273 | NF1 | chr17 | 29560231 | + | ENST00000359872 | ASIC2 | chr17 | 31439085 | - | 5953 | 4091 | 254 | 5074 | 1606 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000356175 | ENST00000225823 | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - | 0.000539394 | 0.99946064 |
ENST00000356175 | ENST00000359872 | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - | 0.000539394 | 0.99946064 |
ENST00000358273 | ENST00000225823 | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - | 0.000539394 | 0.99946064 |
ENST00000358273 | ENST00000359872 | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - | 0.000539394 | 0.99946064 |
Top |
Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >58671_58671_1_NF1-ASIC2_NF1_chr17_29560231_ENST00000356175_ASIC2_chr17_31439085_ENST00000225823_length(amino acids)=1606AA_BP=1279 MGACTPQTLSLPLPSPQPPLPALFPAQGAGPPFPPPPPGRGEDMAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINIS KYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNS ASGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENY PDEFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLT ESAAIACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFH YVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHPAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMV KLIHADPKLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTS HQMLSSTEILKWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTP PICRQAQTKLEVALYMFLWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIE HPTAGNTEAWEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSN SGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDS QGQVLLTDTNTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRVLGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKF RNKMVEYLTDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQT GGRKRGMSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGD QGELPIAMALANVVPCSQWVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPF IQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPA LGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQM -------------------------------------------------------------- >58671_58671_2_NF1-ASIC2_NF1_chr17_29560231_ENST00000356175_ASIC2_chr17_31439085_ENST00000359872_length(amino acids)=1606AA_BP=1279 MGACTPQTLSLPLPSPQPPLPALFPAQGAGPPFPPPPPGRGEDMAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINIS KYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNS ASGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENY PDEFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLT ESAAIACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFH YVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHPAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMV KLIHADPKLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTS HQMLSSTEILKWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTP PICRQAQTKLEVALYMFLWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIE HPTAGNTEAWEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSN SGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDS QGQVLLTDTNTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRVLGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKF RNKMVEYLTDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQT GGRKRGMSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGD QGELPIAMALANVVPCSQWVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPF IQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPA LGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQM -------------------------------------------------------------- >58671_58671_3_NF1-ASIC2_NF1_chr17_29560231_ENST00000358273_ASIC2_chr17_31439085_ENST00000225823_length(amino acids)=1606AA_BP=1279 MGACTPQTLSLPLPSPQPPLPALFPAQGAGPPFPPPPPGRGEDMAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINIS KYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNS ASGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENY PDEFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLT ESAAIACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFH YVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHPAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMV KLIHADPKLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTS HQMLSSTEILKWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTP PICRQAQTKLEVALYMFLWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIE HPTAGNTEAWEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSN SGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDS QGQVLLTDTNTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRVLGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKF RNKMVEYLTDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQT GGRKRGMSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGD QGELPIAMALANVVPCSQWVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPF IQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPA LGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQM -------------------------------------------------------------- >58671_58671_4_NF1-ASIC2_NF1_chr17_29560231_ENST00000358273_ASIC2_chr17_31439085_ENST00000359872_length(amino acids)=1606AA_BP=1279 MGACTPQTLSLPLPSPQPPLPALFPAQGAGPPFPPPPPGRGEDMAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINIS KYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNS ASGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENY PDEFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLT ESAAIACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFH YVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHPAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMV KLIHADPKLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTS HQMLSSTEILKWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTP PICRQAQTKLEVALYMFLWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIE HPTAGNTEAWEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSN SGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDS QGQVLLTDTNTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRVLGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKF RNKMVEYLTDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQT GGRKRGMSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGD QGELPIAMALANVVPCSQWVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPF IQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPA LGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQM -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:29560231/chr17:31439085) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
NF1 | ASIC2 |
FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity. {ECO:0000269|PubMed:2121371, ECO:0000269|PubMed:8417346}. | FUNCTION: Cation channel with high affinity for sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Also permeable for Li(+) and K(+). Generates a biphasic current with a fast inactivating and a slow sustained phase. Heteromeric channel assembly seems to modulate. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000225823 | 0 | 10 | 449_512 | 236.0 | 564.0 | Topological domain | Cytoplasmic | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000359872 | 0 | 10 | 449_512 | 185.0 | 513.0 | Topological domain | Cytoplasmic | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000225823 | 0 | 10 | 428_448 | 236.0 | 564.0 | Transmembrane | Helical | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000359872 | 0 | 10 | 428_448 | 185.0 | 513.0 | Transmembrane | Helical |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000356175 | + | 27 | 57 | 1352_1355 | 1236.0 | 2819.0 | Compositional bias | Note=Poly-Ser |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000358273 | + | 27 | 58 | 1352_1355 | 1236.0 | 2840.0 | Compositional bias | Note=Poly-Ser |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000431387 | + | 1 | 15 | 1352_1355 | 0 | 594.0 | Compositional bias | Note=Poly-Ser |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000356175 | + | 27 | 57 | 1235_1451 | 1236.0 | 2819.0 | Domain | Ras-GAP |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000356175 | + | 27 | 57 | 1580_1738 | 1236.0 | 2819.0 | Domain | CRAL-TRIO |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000358273 | + | 27 | 58 | 1235_1451 | 1236.0 | 2840.0 | Domain | Ras-GAP |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000358273 | + | 27 | 58 | 1580_1738 | 1236.0 | 2840.0 | Domain | CRAL-TRIO |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000431387 | + | 1 | 15 | 1235_1451 | 0 | 594.0 | Domain | Ras-GAP |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000431387 | + | 1 | 15 | 1580_1738 | 0 | 594.0 | Domain | CRAL-TRIO |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000356175 | + | 27 | 57 | 2555_2571 | 1236.0 | 2819.0 | Motif | Note=Bipartite nuclear localization signal |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000358273 | + | 27 | 58 | 2555_2571 | 1236.0 | 2840.0 | Motif | Note=Bipartite nuclear localization signal |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000431387 | + | 1 | 15 | 2555_2571 | 0 | 594.0 | Motif | Note=Bipartite nuclear localization signal |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000356175 | + | 27 | 57 | 1580_1837 | 1236.0 | 2819.0 | Region | Note=Lipid binding |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000358273 | + | 27 | 58 | 1580_1837 | 1236.0 | 2840.0 | Region | Note=Lipid binding |
Hgene | NF1 | chr17:29560231 | chr17:31439085 | ENST00000431387 | + | 1 | 15 | 1580_1837 | 0 | 594.0 | Region | Note=Lipid binding |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000225823 | 0 | 10 | 1_37 | 236.0 | 564.0 | Topological domain | Cytoplasmic | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000225823 | 0 | 10 | 59_427 | 236.0 | 564.0 | Topological domain | Extracellular | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000359872 | 0 | 10 | 1_37 | 185.0 | 513.0 | Topological domain | Cytoplasmic | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000359872 | 0 | 10 | 59_427 | 185.0 | 513.0 | Topological domain | Extracellular | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000225823 | 0 | 10 | 38_58 | 236.0 | 564.0 | Transmembrane | Helical | |
Tgene | ASIC2 | chr17:29560231 | chr17:31439085 | ENST00000359872 | 0 | 10 | 38_58 | 185.0 | 513.0 | Transmembrane | Helical |
Top |
Fusion Protein Structures |
PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
PDB file (971)CIF file (971) >>>971.cif | NF1 | chr17 | 29560231 | + | ASIC2 | chr17 | 31439085 | - | MGACTPQTLSLPLPSPQPPLPALFPAQGAGPPFPPPPPGRGEDMAAHRPV EWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINISKYKFSLVISG LTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKDTMRLDET MLVKQLLPEICHFLHTCREGNQHAAELRNSASGVLFSLSCNNFNAVFSRI STRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFKFKALKKV AQLAVINSLEKAFWNWVENYPDEFTKLYQIPQTDMAECAEKLFDLVDGFA ESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFLDSLRKAL AGHGGSRQLTESAAIACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLL FNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFH YVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAH PAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLIHADPKLL LCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDS IDLWNPDAPVETFWEISSQMLFYICKKLTSHQMLSSTEILKWLREILICR NKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPGAS LRKGKGNSSMDSAAGCSGTPPICRQAQTKLEVALYMFLWNPDTEAVLVAM SCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMSTGRAALQK RVMALLRRIEHPTAGNTEAWEDTHAKWEQATKLILNYPKAKMEDGQAAES LHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSN SGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHE KVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDSQGQVLLTDTN TQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRVLGNMVH AIQIKTKLCQLVEVMMARRDDLSFCQEMKFRNKMVEYLTDWVMGTSNQAA DDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKSQLFLKYF TLFMNLLNDCSEVEDESAQTGGRKRGMSRRLASLRHCTVLAMSNLLNANV DSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETVLADRFER LVELVTMMGDQGELPIAMALANVVPCSQWVFTKYGKCYMFNSGEDGKPLL TTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPF IQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITA CRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPALGLLAEKDSN YCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLD IFFEALNYETIEQKKAYEVAALLGDIGGQMGLFIGASILTILELFDYIYE LIKEKLLDLLGKEEDEGSHDENVSTCDTMPNHSETISHTVNVPLQTTLGT | 1606 |
3D view using mol* of 971 (AA BP:) | ||||||||||
Top |
pLDDT score distribution |
pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
NF1_pLDDT.png |
ASIC2_pLDDT.png |
pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
NF1_ASIC2_971_pLDDT_and_active_sites.png (AA BP:) |
NF1_ASIC2_971_violinplot.png (AA BP:) |
Top |
Ramachandran Plot of Fusion Protein Structure |
Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
Fusion AA seq ID in FusionPDB and their Ramachandran plots |
Top |
Potential Active Site Information |
The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
971 | 1.067 | 258 | 1.113 | 967.26 | 0.516 | 0.734 | 0.944 | 1.071 | 0.82 | 1.306 | 0.913 | Chain A: 628,631,633,634,635,636,637,638,736,737,7 39,740,741,742,743,745,826,829,830,833,834,836,837 ,840,851,852,854,855,856,858,859,869,870,871,872,8 73,874,875,876,877,879,880,883,949,951,952,955 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide. |
Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
Drug information from DrugBank of the top 20 interacting small molecules. |
ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9) |
ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
Toxicity information of individual drugs using eToxPred |
ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
Gene | PPI interactors |
NF1 | HRAS, SMARCA4, POLR2A, TIRAP, SIRT7, VCP, NSFL1C, CAV1, YWHAB, FAF2, NXF1, CCDC8, HLA-DPA1, EFNB2, CD274, TNFSF13B, CA14, SLAMF1, VSIG4, TGOLN2, HTR6, NOSIP, KRAS, CLK1, CDC5L, APP, YWHAH, PML, TRAF6, PTEN, SDC2, EGFR, CD79B, P4HA3, SCN3B, VSIG1, SIGLECL1, EPHA1, FAM174A, KCTD3, KIF13B, ZBTB21, KSR1, CGN, GIGYF1, LRFN1, RTKN, MAST3, DENND1A, SH3PXD2A, SRGAP2, DENND4C, PPM1H, EIF4E2, SIPA1L1, LIMA1, RALGPS2, MAGI1, CBY1, TESK2, CDC25C, DCLK1, GIGYF2, HDAC4, LPIN3, ZNF638, CAMSAP2, NADK, MAPKAP1, SRSF12, RASAL2, SYDE1, KIAA1804, TIAM1, AGAP1, CDC25B, CDK16, SH3RF3, PHLDB2, PLEKHA7, KIF1C, OSBPL6, FAM110B, USP21, NAV1, TANC2, PTPN13, FAM53C, ANKRD34A, STARD13, PTPN14, GAB2, DENND4A, INPP5E, TOP1, TOP2A, TOP3A, NRAS, ZUFSP, ESR2, LZTR1, SPRED1, MYC, LIMK2, KIAA1429, CTDP1, DYRK1A, F12, AKT1, EPHA2, MAP2K3, RAF1, SOX4, BIRC3, ORF7a, LCK, NOLC1, N, nsp7, KIF14, PRC1, MKI67, FASN, NR3C1, DDRGK1, FLOT1, LYN, PFN1, RHOB, ATG7, EFS, C19orf38, CDHR2, ITFG3, CD80, SEMA4C, DGCR2, EFNA4, PTGES2, LRRC25, EVI2A, EFNB1, TPST2, C3orf18, GYPA, HCST, TACSTD2, OPALIN, IL2RA, CD226, SIRT6, |
Protein-protein interactors based on sequence similarity (STRING) |
Gene | STRING network |
NF1 | |
ASIC2 |
- Retained interactions in fusion protein (protein functional feature from UniProt). |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost interactions due to fusion (protein functional feature from UniProt). |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to NF1-ASIC2 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to NF1-ASIC2 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | NF1 | C0027831 | Neurofibromatosis 1 | 44 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | NF1 | C1708353 | Hereditary Paraganglioma-Pheochromocytoma Syndrome | 10 | CLINGEN |
Hgene | NF1 | C0349639 | Juvenile Myelomonocytic Leukemia | 7 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | NF1 | C2931482 | Neurofibromatosis-Noonan syndrome | 6 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | NF1 | C0553586 | Cafe-au-lait macules with pulmonary stenosis | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | NF1 | C0162678 | Neurofibromatoses | 3 | CGI;CTD_human;GENOMICS_ENGLAND |
Hgene | NF1 | C0004114 | Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0023467 | Leukemia, Myelocytic, Acute | 2 | CTD_human |
Hgene | NF1 | C0025202 | melanoma | 2 | CGI;CTD_human |
Hgene | NF1 | C0026998 | Acute Myeloid Leukemia, M1 | 2 | CTD_human |
Hgene | NF1 | C0205768 | Subependymal Giant Cell Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0206727 | Nerve Sheath Tumors | 2 | CTD_human |
Hgene | NF1 | C0280783 | Juvenile Pilocytic Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0280785 | Diffuse Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0334579 | Anaplastic astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0334580 | Protoplasmic astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0334581 | Gemistocytic astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0334582 | Fibrillary Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0334583 | Pilocytic Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0338070 | Childhood Cerebral Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0547065 | Mixed oligoastrocytoma | 2 | CTD_human |
Hgene | NF1 | C0750935 | Cerebral Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0750936 | Intracranial Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C0751689 | Peripheral Nerve Sheath Neoplasm | 2 | CTD_human |
Hgene | NF1 | C0751691 | Perineurioma | 2 | CTD_human |
Hgene | NF1 | C1704230 | Grade I Astrocytoma | 2 | CTD_human |
Hgene | NF1 | C1834235 | NEUROFIBROMATOSIS, FAMILIAL SPINAL | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | NF1 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 2 | CTD_human |
Hgene | NF1 | C0001430 | Adenoma | 1 | CTD_human |
Hgene | NF1 | C0004352 | Autistic Disorder | 1 | CTD_human |
Hgene | NF1 | C0016057 | Fibrosarcoma | 1 | CTD_human |
Hgene | NF1 | C0017636 | Glioblastoma | 1 | CTD_human |
Hgene | NF1 | C0017638 | Glioma | 1 | CGI;CTD_human |
Hgene | NF1 | C0020796 | Profound Mental Retardation | 1 | CTD_human |
Hgene | NF1 | C0023186 | Learning Disorders | 1 | CTD_human |
Hgene | NF1 | C0023827 | liposarcoma | 1 | CTD_human |
Hgene | NF1 | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
Hgene | NF1 | C0026654 | Moyamoya Disease | 1 | GENOMICS_ENGLAND |
Hgene | NF1 | C0027809 | Neurilemmoma | 1 | CTD_human |
Hgene | NF1 | C0027830 | neurofibroma | 1 | CTD_human |
Hgene | NF1 | C0027962 | Melanocytic nevus | 1 | CTD_human |
Hgene | NF1 | C0028326 | Noonan Syndrome | 1 | GENOMICS_ENGLAND |
Hgene | NF1 | C0031511 | Pheochromocytoma | 1 | CTD_human |
Hgene | NF1 | C0035320 | Retinal Neovascularization | 1 | CTD_human |
Hgene | NF1 | C0205646 | Adenoma, Basal Cell | 1 | CTD_human |
Hgene | NF1 | C0205647 | Follicular adenoma | 1 | CTD_human |
Hgene | NF1 | C0205648 | Adenoma, Microcystic | 1 | CTD_human |
Hgene | NF1 | C0205649 | Adenoma, Monomorphic | 1 | CTD_human |
Hgene | NF1 | C0205650 | Papillary adenoma | 1 | CTD_human |
Hgene | NF1 | C0205651 | Adenoma, Trabecular | 1 | CTD_human |
Hgene | NF1 | C0205824 | Liposarcoma, Dedifferentiated | 1 | CTD_human |
Hgene | NF1 | C0205825 | Liposarcoma, Pleomorphic | 1 | CTD_human |
Hgene | NF1 | C0205944 | Sarcoma, Epithelioid | 1 | CTD_human |
Hgene | NF1 | C0205945 | Sarcoma, Spindle Cell | 1 | CTD_human |
Hgene | NF1 | C0259783 | mixed gliomas | 1 | CTD_human |
Hgene | NF1 | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human |
Hgene | NF1 | C0555198 | Malignant Glioma | 1 | CTD_human |
Hgene | NF1 | C0751262 | Adult Learning Disorders | 1 | CTD_human |
Hgene | NF1 | C0751263 | Learning Disturbance | 1 | CTD_human |
Hgene | NF1 | C0751265 | Learning Disabilities | 1 | CTD_human |
Hgene | NF1 | C0751374 | Schwannomatosis, Plexiform | 1 | CTD_human |
Hgene | NF1 | C0917816 | Mental deficiency | 1 | CTD_human |
Hgene | NF1 | C0917817 | Neurofibromatosis 3 | 1 | CTD_human |
Hgene | NF1 | C1257877 | Pheochromocytoma, Extra-Adrenal | 1 | CTD_human |
Hgene | NF1 | C1261473 | Sarcoma | 1 | CTD_human |
Hgene | NF1 | C1330966 | Developmental Academic Disorder | 1 | CTD_human |
Hgene | NF1 | C1370889 | Liposarcoma, well differentiated | 1 | CTD_human |
Hgene | NF1 | C1621958 | Glioblastoma Multiforme | 1 | CTD_human |
Hgene | NF1 | C3150928 | NF1 Microdeletion Syndrome | 1 | ORPHANET |
Hgene | NF1 | C3714756 | Intellectual Disability | 1 | CTD_human |
Tgene | ASIC2 | C0004352 | Autistic Disorder | 1 | CTD_human |
Tgene | ASIC2 | C0021368 | Inflammation | 1 | CTD_human |